Former Icahn MD’s Sarissa Capital Discloses 6.2% of Ariad Pharmaceuticals

According to a new filing with the SEC, Sarissa Capital Management now holds around 11.5 million shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), with an aggregate value of some $43.6 million, at the current stock price of the company. The position held by Sarissa  amasses about 6.2% of Ariad’s common stock.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Alex Denner used to work for Carl Icahn between 2006 and 2011. Sarissa Capital is an activist healthcare focused hedge fund with a long bias. The fund was launched earlier in 2013.

Disclosure: none

Recommended Reading:

Dan Gold’s QVT Ups Stake in Oncothyreon to 5.8%

David Blood and Al Gore Decrease Position in Kingspan Group to 8.7%

The 10 Main Hedge Fund Moves of the Past Seven Days